A Low-Therapeutic Dose of Lithium Inhibits GSK3 and Enhances Myoblast Fusion in C2C12 Cells

A Low-Therapeutic Dose of Lithium Inhibits GSK3 and Enhances Myoblast Fusion in C2C12 Cells

Glycogen synthase kinase 3 (GSK3) slows myogenic differentiation and myoblast fusion partly by inhibiting the Wnt/&#946;-catenin signaling pathway. Lithium, a common medication for bipolar disorder, inhibits GSK3 via Mg<sup>+</sup> competition and increased Ser21 (GSK3&#945;) or...

Full description

Bibliographic Details
Main Authors: Nigel Kurgan, Kennedy C. Whitley, Lucas A. Maddalena, Fereshteh Moradi, Joshua Stoikos, Sophie I. Hamstra, Elizabeth A. Rubie, Megha Kumar, Brian D. Roy, James R. Woodgett, Jeffrey A. Stuart, Val A. Fajardo
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Cells
Subjects:
lithium
glycogen synthase kinase 3
myoblast fusion
Online Access:https://www.mdpi.com/2073-4409/8/11/1340

Internet

https://www.mdpi.com/2073-4409/8/11/1340

Similar Items